Form 4: MAXCYTE Director Sells Shares Under 10b5-1 Plan

MAXCYTE Director Rekha Hemrajani sold 10,684 shares of common stock for a weighted average price of $2.0945 per share, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Rekha Hemrajani, a Director of MAXCYTE, INC. (MXCT), disposed of 10,684 shares of common stock.
• The transaction occurred on June 25, 2025.
• The shares were sold at a weighted average price of $2.0945 per share, with individual sales ranging from $2.07 to $2.1212.
• The sale was executed under a Rule 10b5-1 trading plan adopted by Ms. Hemrajani on March 18, 2025.
• Following this transaction, Ms. Hemrajani beneficially owns 39,893 shares of MAXCYTE common stock directly.

Sentiment

Score: 4

Explanation: The sale of shares by a director was conducted under a pre-arranged Rule 10b5-1 trading plan, which mitigates the negative sentiment of an insider sale. However, the significant delay in filing this Form 4 (transaction date June 25, 2025, filed August 27, 2025) raises concerns about compliance and transparency, leading to a slightly negative sentiment.

Negatives

• A director selling a significant number of shares (10,684) could be perceived negatively by some investors, as it reduces their direct stake in the company.
• The Form 4 filing appears to be significantly delayed, as the transaction date of June 25, 2025, precedes the filing signature date of August 27, 2025, which is beyond the typical two-business-day reporting requirement for Form 4s.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May perceive a slight negative signal due to reduced insider ownership, though mitigated by the 10b5-1 plan. The late filing could also raise concerns about transparency and compliance.

Key Dates

Recommendation

While the insider sale was pre-planned under a 10b5-1 plan, the significant delay in filing this Form 4 (over two months after the transaction date) raises compliance concerns. Investors should monitor for any further information regarding this delay or other insider activity. Based solely on this filing, a 'hold' recommendation is appropriate, acknowledging both the planned nature of the sale and the regulatory reporting issue.

Keywords

MAXCYTE, MXCT, Form 4, Insider Sale, Director, Rekha Hemrajani, 10b5-1 Plan, Common Stock, Share Sale